• Skip to main content
  • Skip to primary sidebar

  • Home
  • About
    • Overview
    • Owners and Intermediaries
    • Management Teams
    • Investors
  • Strategy
    • Overview
    • Disciplined Sector Focus
    • Long-Term Business Improvement
    • Investment Criteria & Transaction Profile
  • Sustainability
    • ESG Principles
    • Implementation
    • Core Areas
    • SK Portfolio EcoVadis Ratings
    • SKCP ESG Report
  • Portfolio
  • Team
  • News
  • Contact
  • Investor Login

Portfolio

/ December 10, 2017

Wavelength

Wavelength

Wavelength is a leading developer and manufacturer of generic APIs and finished dose forms (“FDF”) with operations primarily located in Israel. Wavelength supports a global, blue-chip customer base and has a broad array of products that leverage its specialized manufacturing capabilities (including cytotoxic, steroid and high potency) and core competency in complex chemistries.

SK Capital acquired Wavelength in November 2017.

For more information, please visit: http://www.wavelengthpharma.com/

 

Primary Sidebar

Related News

  • Five years after its entry into the capital of SEQENS, Eurazeo announces that it has entered into exclusive discussions to sell its stake in SEQENS. The deal is expected to close by the end of 2021.

    August 27, 2021
  • Wavelength Pharmaceuticals Names Iftach Seri as Chief Executive Officer and Tami Cohen as Chief Financial Officer

    November 30, 2017
  • SK Capital Closes Acquisition of Perrigo’s API Business and Changes Name to Wavelength Pharmaceuticals

    November 21, 2017

SK Capital Portfolio Companies

  • Luxium Solutions
  • VanDeMark Chemical, Inc
  • Valtris Specialty Chemicals
  • Florachem
  • Heubach
  • Seqens
  • Deltech LLC
  • Canlak
  • IPACKCHEM
  • Woodstock Sterile Solutions
  • Lacerta Group
  • Venator
  • Tilley Distribution
  • NuCera Solutions
  • Techmer PM
  • GEON
  • SI Group
  • Perimeter Solutions
  • Wavelength
  • Foremark
  • Tri-Tex
  • Niacet
  • Noramco
  • Extractas Bioscience
  • Purisys
  • Archroma
  • Addivant
  • TPC Group
  • Ascend
  • IBA Molecular
  • Calabrian Corporation
  • Halo Pharmaceutical
  • AEB Group

To request for a copy of our ESG report, please click here.

© 2023 SK Capital Partners. All Rights Reserved.

Important Disclosures

  • Home
  • About
    • Overview
    • Owners and Intermediaries
    • Management Teams
    • Investors
    • Back
  • Strategy
    • Overview
    • Disciplined Sector Focus
    • Long-Term Business Improvement
    • Investment Criteria & Transaction Profile
    • Back
  • Sustainability
    • ESG Principles
    • Implementation
    • Core Areas
    • SK Portfolio EcoVadis Ratings
    • SKCP ESG Report
    • Back
  • Portfolio
  • Team
  • News
  • Contact
  • Investor Login